Swedish Orphan Biovitrum (OTCMKTS:SWTUY) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report issued on Thursday.
According to Zacks, “Swedish Orphan Biovitrum AB is a biopharmaceutical company which develops and makes drugs for patients with rare diseases. Its product portfolio primarily includes Kineret within the inflammation therapeutic area, Orfadin, Ammonaps and Ammonul within the genetics and metabolic therapeutic which are in clinical trial stage. Swedish Orphan Biovitrum AB is headquartered in Stockholm, Sweden. “
Shares of SWTUY stock opened at $17.41 on Thursday. Swedish Orphan Biovitrum has a 1 year low of $12.55 and a 1 year high of $17.70. The firm has a market cap of $4,744.36, a PE ratio of 49.74, a PEG ratio of 0.77 and a beta of 1.52.
Swedish Orphan Biovitrum AB (publ), an integrated biopharmaceutical company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haemophilia, inflammation, and genetics and metabolism diseases primarily in Sweden and internationally. Its core products include Kineret for the treatment of rheumatoid arthritis and neonatal-onset multisystem inflammatory disease; Orfadin for the treatment of hereditary tyrosinaemia type 1 genetic disorder; and Xiapex for the treatment of Dupuytren's contracture and Peyronie's disease.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Swedish Orphan Biovitrum Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Swedish Orphan Biovitrum and related companies with MarketBeat.com's FREE daily email newsletter.